SCIENCE NEWS
Enzyme Action Could Be Target for Diabetes, Heart Disease Treatments
Cardiac researchers have found a new cellular pathway that could help in developing therapeutic treatments for obesity-related disorders, like diabetes and heart disease. [Press release from the University of Cincinnati discussing research presented at the American Heart Association’s Scientific Sessions 2010]
Fetal Programming in Diabetes
Babies born to women who have high blood sugar (gestational diabetes) during pregnancy face a greater risk for developing obesity and Type 2 diabetes later on. Although elevated blood sugar levels can be mild for diabetic mothers who take precautions, the excess glucose crossing the placenta into their babies may seriously affect the pancreatic beta cells. [University of Arizona Press Release]
|
|
INDUSTRY NEWS
Juvenile Diabetes Research Foundation and Amylin Pharmaceuticals Partner to Investigate Metreleptin as Potential Therapy to Improve Blood Glucose Control in Type 1 Diabetes
The Juvenile Diabetes Research Foundation and Amylin Pharmaceuticals, Inc. announced that they entered into a research collaboration agreement to provide financial support for a clinical proof-of-concept study to investigate the effects of metreleptin, an analog of the human hormone leptin, in patients with type 1 diabetes. [Amylin Pharmaceuticals, Inc. Press Release]
DiaMedica Announces Research Collaboration with The Sanford Project, a Leading Type 1 Diabetes Research Center
DiaMedica Inc. announced the commencement of a research collaboration with The Sanford Project, a world leader in type 1 diabetes research. [DiaMedica Inc. Press Release]
Pfizer Launches Global Centers for Therapeutic Innovation, a Network of Research Partnerships, with University of California, San Francisco
Pfizer Inc. announced the establishment of the Global Centers for Therapeutic Innovation, an entrepreneurial network of partnerships with leading academic medical centers to transform research and development by accessing leading translational researchers. [Pfizer Inc. Press Release]
American Pharmacists Association Foundation Joins the Bristol-Myers Squibb Foundation’s $100 Million National Diabetes Initiative
The American Pharmacists Association Foundation announced it has been selected as an initial grantee in and will play a major role in the new Together on Diabetes®: Communities Uniting to Meet America’s Diabetes Challenge. [American Pharmacists Association Foundation Press Release]
Major Gift from Judy and J. John Goodman Supports Scripps Florida
The Scripps Research Institute has announced a $50,000 gift from Palm Beach residents Judy and J. John Goodman, M.D., to Scripps Florida. The gift will support both the work of Professor Thomas Kodadek in the development of a new approach to detect and treat Type I diabetes, as well as the Scripps Research graduate program endowment. [The Scripps Research Institute Press Release]
Oramed Pharmaceuticals Presents Results of Its Phase IIb Clinical Trial at the Diabetes Technology Meeting
Oramed Pharmaceuticals Inc. presented the results of its recently completed Phase IIb trial. The multicenter, placebo-controlled, randomized, double blind study conducted in 29 patients with type 2 diabetes assessed the safety of ORMD-0801 in patients with Type II diabetes. [Oramed Pharmaceuticals Inc. Press Release]
Study Highlights Incidence of Cardiovascular Disease-Related Events and All-Cause Hospitalizations Associated with BYETTA® Compared to Insulin, Thiazolidinediones, Sulfonylureas, Metformin and Januvia®
Amylin Pharmaceuticals, Inc. and Eli Lilly and Company announced results from a retrospective study of nearly 375,000 type 2 diabetes patients evaluating the incidence of events related to cardiovascular disease and all-cause hospitalizations among initiators of BYETTA® (exenatide) injection compared to initiators of other commonly used diabetes medications. [Amylin Pharmaceuticals, Inc. Press Release]
Neogenix Oncology® Receives Patent for Its Monoclonal Antibody, 16C3, for Colorectal and Pancreatic Cancer
Neogenix Oncology, Inc. announced that the U.S. Patent and Trademark Office has issued patent number 7,829,678 B2, with claims relating to 16C3 antibody, the company’s monoclonal antibody for colorectal and pancreatic cancer. [Business Wire]
AVEO’s Tivozanib in Combination with FOLFOX6 Demonstrates Anti-Tumor Activity and Safety in Advanced GI Cancers
AVEO Pharmaceuticals, Inc. announced results from a Phase Ib clinical trial evaluating the company’s lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with FOLFOX6, a standard chemotherapy regimen, in patients with advanced gastrointestinal (GI) cancers. [AVEO Pharmaceuticals, Inc. Press Release]
Follow-Up Data from Threshold Pharmaceuticals’ Phase I/II Clinical Trials of TH-302 Demonstrate Broad Activity in All Combinations Against Multiple Tumor Types
Threshold Pharmaceuticals, Inc. announced clinical trial results related to Threshold’s clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. [Threshold Pharmaceuticals, Inc. Press Release]
New National Surgical Centre for Pancreatic Cancer at St. Vincent’s Hospital
The Minister for Health and Children officially opened the new Health Service Executive National Cancer Control Program National Surgical Centre for Pancreatic Cancer at St. Vincent’s University Hospital, Dublin. [Health Service Executive Press Release]
Pancreatic Cancer UK Launches Study for Survival — The UK’s First Comprehensive Mapping of the Views and Experiences of People Living with and Treating Pancreatic Cancer
Pancreatic Cancer UK, launched Study for Survival, which is the UK’s first comprehensive mapping of the views and experiences of people living and working with pancreatic cancer. [Pancreatic Cancer UK Press Release]
The United States of Diabetes: New Report Shows Half the Country Could Have Diabetes or Prediabetes at a Cost of $3.35 Trillion by 2020
More than 50 percent of Americans could have diabetes or prediabetes by 2020 at a cost of $3.35 trillion over the next decade if current trends continue, according to new analysis by UnitedHealth Group’s Center for Health Reform and Modernization, but there are also practical solutions for slowing the trend. [UnitedHealth Group Press Release]
Joint IDF-CDS Study Reveals Impact of Diabetes in China
The International Diabetes Federation (IDF) and the Chinese Diabetes Society of the Chinese Medical Association (CDS) launched the findings of a new study revealing the social and economic impact of diabetes in China. [International Diabetes Federation Press Release]
|
|
EVENTS (Listed by Date)
Pharmacology in Stem Cells Research and Regenerative Medicine
December 17, 2010
London, United Kingdom
The 3rd Guangzhou International Conference on Stem Cell Biology and Regenerative Medicine
December 17-19, 2010
Guangzhou, China
Type 2 Diabetes, Insulin Resistance and Metabolic Dysfunction
January 12-17, 2011
Dillon, United States
Keystone Symposia: Obesity
January 12-17, 2011
Keystone, United States
2011 Gastrointestinal Cancers Symposium
January 20-22, 2011
San Francisco, United States
Keystone Symposia: Epithelial Plasticity and Epithelial to Mesenchymal Transition
January 21-26, 2011
Vancouver, Canada
5th Annual Stem Cells and Regenerative Medicine World Congress
January 24-25, 2011
San Diego, United States
Phacilitate 7th Annual Cell & Gene Therapy Forum 2011
January 24-26, 2011
Washington, D.C., United States
Early Development for Innovative Diabetes & Metabolic Syndrome Therapeutics Conference
January 26-27, 2011
Amsterdam, The Netherlands
Joint Conference of the International Association of Pancreatology and the Indian Pancreas Club
February 10-13, 2011
Maradu, India
2nd Annual International Diabetes Summit
February 22-24, 2011
Dubai, United Arab Emirates
United Kingdom National Stem Cell Network 2011 Annual Scientific Conference
March 30-April 1, 2011
York, United Kingdom
American Association for Cancer Research (AACR) 102nd Annual Meeting 2011
April 2-6, 2011
Orlando, United States
13th Annual C21 BioVentures
May 24-26, 2011
Napa, United States
European Pancreatic Club Meeting 2011
June 22-25, 2011
Magdeburg, Germany
PancreasFest 2011
July 28-30, 2011
Pittsburgh, United States
Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.
JOB OPPORTUNITIES
Lab Technologist – Human Embryonic and Induced Pluripotent Stem Cells (STEMCELL Technologies)
Lab Technologist – Tissue Culture (STEMCELL Technologies)
Product Manager – Pluripotent Stem Cells (STEMCELL Technologies)
Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News at no cost.
Visit here to post your career opportunities.
Have we missed an important article or publication in Pancreatic Cell News? Click here to submit!
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
